ArticleEuropean urology oncology2022
Predicting Oncologic Outcomes in Small Renal Tumors.
Article in European urology oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Metastatic tropism of molecularly defined clear-cell renal cell carcinoma clusters.The Journal of clinical investigation · 2026Trial
- Molecular underpinnings of metastatic small renal masses.JCI insight · 2026Article
- BAP1 and PBRM1 Loss Is Associated with Aggressive Clinicopathological Features in Clear Cell Renal Cell Carcinoma: Prognostic Implications in a 10-Year Surgical Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- Robot-assisted partial nephrectomy during simultaneous extracorporeal membrane oxygenation and impella®in a candidate for left ventricular assist device as a bridge for cardiac transplant: a case report.The Canadian journal of urology · 2026Article
- Perioperative outcomes after Robot-assisted partial nephrectomy for very small (≤ 2 cm) versus larger small (> 2-4 cm) renal tumors: a multi-institutional propensity score-matched study.Journal of robotic surgery · 2026Article
- Determinants of late metastases in renal cell carcinoma.Journal of the National Cancer Institute · 2025Article
- Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial.Nature communications · 2025Article
- In Pursuit of KI-RADS: Toward a Single, Evidence-based Imaging Classification of Renal Masses.Radiology · 2025Review
- Differences in mutations across tumour sizes in clear-cell renal cell carcinoma.BJU international · 2025Article
- Multiparameter computed tomography (CT) radiomics signature fusion-based model for the preoperative prediction of clear cell renal cell carcinoma nuclear grade: a multicenter development and external validation study.Quantitative imaging in medicine and surgery · 2024Article
- The evolving management of small renal masses.Nature reviews. Urology · 2024Review
- Histopathology Based AI Model Predicts Anti-Angiogenic Therapy Response in Renal Cancer Clinical Trial.ArXiv · 2024Article
- Molecular underpinnings of dedifferentiation and aggressiveness in chromophobe renal cell carcinoma.JCI insight · 2024Article
- Small Renal Masses: The Evolving Histologic, Imaging, and Genomic Landscapes.Journal of clinical medicine · 2023Article
- The expanding role of BAP1 in clear cell renal cell carcinoma.Human pathology · 2023Review
- Management of stage 1 renal cell cancer in patients immunosuppressed for organ transplantation or autoimmune disease.Frontiers in urology · 2023Article
- Deep Learning Identification of Clear Cell Renal Cell Carcinoma on MR Imaging.Journal of computer assisted tomographyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundMost patients diagnosed with renal cancer today present with small renal masses (SRMs). Although these patients have a low risk of dying from their disease and many are followed with active surveillance protocols, a small subset of renal cell carcinomas (RCCs) behave aggressively. Knowledge regarding features of aggressive behavior would enable better adoption of active surveillance strategies among these patients.
objectiveWe sought to improve prognostic models to predict metastasis-free survival after nephrectomy through focused analyses of clinicopathologic characteristics of SRMs associated with adverse outcomes. DESIGN, SETTING, AND
participantsWe identified consecutive patients with surgically resected SRMs (≤4 cm) at the University of Texas Southwestern Kidney Cancer Program between 1998 and 2020. In addition, we evaluated the ability of SRMs to form tumors when implanted in mice, an indicator of tumor aggressiveness. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We examined the clinicopathologic factors associated with metastasis including prospectively performed BAP1 immunohistochemistry at our Clinical Laboratory Improvement Amendments laboratory. Multivariable Cox proportional hazard regression was used to predict metastasis-free survival. RESULTS AND LIMITATIONS: A total of 3900 evaluable nephrectomies (from 3674 ethnically diverse patients) were identified, of which 1984 (51%) were SRMs including 1720 RCC. Of these patients with RCC (SRM
conclusionsWe identified clinicopathologic features that influence metastasis-free survival for patients with SRM PATIENT SUMMARY: We report the identification of features of aggressiveness in small renal tumors that influence the likelihood of metastases after surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.